Abstract
Over the last decade, new psychoactive substances (NPS) have continuously been the focus of the international society since their emergence on the illicit drug market. NPS can be classified into six groups including; synthetic cannabinoid receptor agonists (SCRAs), stimulants, opioids, dissociatives, sedatives/hypnotics, and classic hallucinogens with psychoactive effects. These are sold as “herbal incense,” “bath salts,” “legal highs,” and “research chemicals”. They can be synthesized easily with slight changes in the chemical moieties of known psychoactive substances. NPS are sold worldwide via on- and off-line markets without proper scientific evaluation regarding their safety or harmfulness. Abuse of NPS poses a serious public health issue, and systematic studies on their adverse effects are lacking. Therefore, it would be meaningful to collect currently available data in order to understand NPS and to establish viable solutions to cope with the various health issues related to them. In this article, we reviewed the general pharmacological characteristics, recent findings, and adverse effects of representative NPS; SCRAs. SCRAs are known as the most commonly abused NPS. Most SCRAs, cannabinoid receptor 1 and cannabinoid receptor 2 agonists, are often associated with severe toxicities, including cardiotoxicity, immunotoxicity, and even death, unlike natural cannabinoid Δ9-Tetrahydrocannabinol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alon MH, Saint-Fleur MO (2017) Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respir Med Case Rep 22:137–141. https://doi.org/10.1016/j.rmcr.2017.07.011
Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM (2008) Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod 71:1427–1430. https://doi.org/10.1021/np8002673
Aryana A, Williams MA (2007) Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 118:141–144. https://doi.org/10.1016/j.ijcard.2006.08.001
Asaoka N, Kawai H, Nishitani N, Kinoshita H, Shibui N, Nagayasu K, Shirakawa H, Kaneko S (2016) A new designer drug 5F-ADB activates midbrain dopaminergic neurons but not serotonergic neurons. J Toxicol Sci 41:813–816. https://doi.org/10.2131/jts.41.813
Asbridge M, Hayden JA, Cartwright JL (2012) Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 344:e536. https://doi.org/10.1136/bmj.e536
Ashino T, Hakukawa K, Itoh Y, Numazawa S (2014) Inhibitory effect of synthetic cannabinoids on CYP1A activity in mouse liver microsomes. J Toxicol Sci 39:815–820. https://doi.org/10.2131/jts.39.815
Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837. https://doi.org/10.1002/jms.1558
Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, Torrens M, Pujol J, Farre M, Martin-Santos R (2013) Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS ONE 8:e55821. https://doi.org/10.1371/journal.pone.0055821
Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D (2013) AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 8:523–526. https://doi.org/10.2215/CJN.05690612
Bloomfield MA, Ashok AH, Volkow ND, Howes OD (2016) The effects of Delta(9)-tetrahydrocannabinol on the dopamine system. Nature 539:369–377. https://doi.org/10.1038/nature20153
Brancato A, Cannizzaro C (2018) Mothering under the influence: how perinatal drugs of abuse alter the mother-infant interaction. Rev Neurosci 29:283–294. https://doi.org/10.1515/revneuro-2017-0052
Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 6:e21917. https://doi.org/10.1371/journal.pone.0021917
Busardo FP, Pellegrini M, Klein J, Di Luca NM (2017) Neurocognitive correlates in driving under the influence of cannabis. CNS Neurol Disord Drug Targets 16:534–540. https://doi.org/10.2174/1871527316666170424115455
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41. https://doi.org/10.1016/j.drugalcdep.2014.08.005
Cha HJ, Lee KW, Song MJ, Hyeon YJ, Hwang JY, Jang CG, Ahn JI, Jeon SH, Kim HU, Kim YH, Seong WK, Kang H, Yoo HS, Jeong HS (2014) Dependence potential of the synthetic cannabinoids JWH-073, JWH-081, and JWH-210. in vivo and in vitro approaches. Biomol Ther (Seoul) 22:363–369. https://doi.org/10.4062/biomolther.2014.039
Cha HJ, Seong YH, Song MJ, Jeong HS, Shin J, Yun J, Han K, Kim YH, Kang H, Kim HS (2015) Neurotoxicity of synthetic cannabinoids JWH-081 and JWH-210. Biomol Ther (Seoul) 23:597–603. https://doi.org/10.4062/biomolther.2015.057
Charles R, Holt S, Kirkham N (1979) Myocardial infarction and marijuana. Clin Toxicol 14:433–438. https://doi.org/10.3109/15563657909010604
Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, James LP, Moran JH, Radominska-Pandya A (2011) Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 39:1967–1976. https://doi.org/10.1124/dmd.111.040709
Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH (2013) Sulfaphenazole and alpha-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett 7:34–38. https://doi.org/10.2174/187231280701131211151523
Cohen K, Weinstein AM (2018) Synthetic and Non-synthetic cannabinoid drugs and their adverse effects-a review from public health prospective. Front Public Health 6:162. https://doi.org/10.3389/fpubh.2018.00162
Collins JS, Higginson JD, Boyle DM, Webb SW (1985) Myocardial infarction during marijuana smoking in a young female. Eur Heart J 6:637–638. https://doi.org/10.1093/oxfordjournals.eurheartj.a061913
Cooper ZD (2016) Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 18:52. https://doi.org/10.1007/s11920-016-0694-1
Corazza O, Valeriani G, Bersani FS, Corkery J, Martinotti G, Bersani G, Schifano F (2014) “Spice,” “kryptonite,” “black mamba”: an overview of brand names and marketing strategies of novel psychoactive substances on the web. J Psychoactive Drugs 46:287–294. https://doi.org/10.1080/02791072.2014.944291
Davis C, Boddington D (2015) Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ 24:e162–e163. https://doi.org/10.1016/j.hlc.2015.04.176
Deng H, Verrico CD, Kosten TR, Nielsen DA (2018) Psychosis and synthetic cannabinoids. Psychiatry Res 268:400–412. https://doi.org/10.1016/j.psychres.2018.08.012
Dong C, Chen J, Harrington A, Vinod KY, Hegde ML, Hegde VL (2019) Cannabinoid exposure during pregnancy and its impact on immune function. Cell Mol Life Sci 76:729–743. https://doi.org/10.1007/s00018-018-2955-0
Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, Auwarter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186–1194. https://doi.org/10.1002/jms.1811
Drummer OH, Gerostamoulos D, Woodford NW (2019) Cannabis as a cause of death: A review. Forensic Sci Int 298:298–306. https://doi.org/10.1016/j.forsciint.2019.03.007
EMCDDA (2015a) European Drug Report 2015: Trends and Developments. EMCDDA Web. https://www.emcdda.europa.eu/publications/edr/trends-developments/2015_en. Accessed 22 March 2021.
EMCDDA (2015b) New psychoactive substances in Europe. EMCDDA Web. https://www.emcdda.europa.eu/publications/rapid-communications/new-psychoactive-substances-europe-innovative-legal-responses_en. Accessed 22 March 2021.
Evans-Brown M, Sedefov R (2017) New psychoactive substances: driving greater complexity into the drug problem. Addiction 112:36–38. https://doi.org/10.1111/add.13528
Fergusson DM, Horwood LJ, Northstone K (2002) Maternal use of cannabis and pregnancy outcome. BJOG 109:21–27. https://doi.org/10.1111/j.1471-0528.2002.01020.x
Goyal H, Awad HH, Ghali JK (2017) Role of cannabis in cardiovascular disorders. J Thorac Dis 9:2079–2092. https://doi.org/10.21037/jtd.2017.06.104
Gu SM, Lee HJ, Lee TH, Song YJ, Kim YH, Han KM, Shin J, Park HK, Kim HS, Cha HJ, Yun J (2017) A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CB2 receptors. Naunyn Schmiedebergs Arch Pharmacol 390:1201–1209. https://doi.org/10.1007/s00210-017-1418-8
Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C, Ehiri JE (2016) Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 6:e009986. https://doi.org/10.1136/bmjopen-2015-009986
Hancox JC, Kalk NJ, Henderson G (2020) Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users. Ther Adv Drug Saf 11:2042098620913416. https://doi.org/10.1177/2042098620913416
Hohmann N, Mikus G, Czock D (2014) Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int 111:139–147. https://doi.org/10.3238/arztebl.2014.0139
Holm NB, Nielsen LM, Linnet K (2015) CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48. AAPS J 17:1237–1245. https://doi.org/10.1208/s12248-015-9788-7
Huang WJ, Chen WW, Zhang X (2016) Endocannabinoid system: Role in depression, reward and pain control (Review). Mol Med Rep 14:2899–2903. https://doi.org/10.3892/mmr.2016.5585
Jinwala FN, Gupta M (2012) Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol 22:459–462. https://doi.org/10.1089/cap.2011.0122
Johnston LD, O’malley PM, Bachman JG (2003) Monitoring the future: national results on adolescent drug use: overview of key findings. Focus 1:213–234. https://doi.org/10.1176/foc.1.2.213
Jones RT (2002) Cardiovascular system effects of marijuana. J Clin Pharmacol 42:58S-63S. https://doi.org/10.1002/j.1552-4604.2002.tb06004.x
Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, Lancon C (2014) Acute and long-term effects of cannabis use: a review. Curr Pharm Des 20:4112–4118. https://doi.org/10.2174/13816128113199990620
Karoly HC, Mueller RL, Bidwell LC, Hutchison KE (2020) Cannabinoids and the microbiota-gut-brain axis: emerging effects of cannabidiol and potential applications to alcohol use disorders. Alcohol Clin Exp Res 44:340–353. https://doi.org/10.1111/acer.14256
Khullar V, Jain A, Sattari M (2014) Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones. J Gen Intern Med 29:1200–1204. https://doi.org/10.1007/s11606-014-2802-4
King LA, Kicman AT (2011) A brief history of ‘new psychoactive substances.’ Drug Test Anal 3:401–403. https://doi.org/10.1002/dta.319
Lorenzetti V, Solowij N, Yucel M (2016) The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry 79:e17-31. https://doi.org/10.1016/j.biopsych.2015.11.013
Macfarlane V, Christie G (2015) Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 34:147–153. https://doi.org/10.1111/dar.12225
Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225–232. https://doi.org/10.1016/j.tins.2006.01.008
Manikandan P, Nagini S (2018) Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 19:38–54. https://doi.org/10.2174/1389450118666170125144557
Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, Chillemi E, Bonifaci L, Janiri L, Di Giannantonio M (2015) Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol Clin Exp 30:295–301. https://doi.org/10.1002/hup.2486
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci 10:153. https://doi.org/10.3389/fnins.2016.00153
Mills B, Yepes A, Nugent K (2015) Synthetic cannabinoids. Am J Med Sci 350:59–62. https://doi.org/10.1097/MAJ.0000000000000466
Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:e1622–e1627. https://doi.org/10.1542/peds.2010-3823
NIDA (2020) Monitoring the future study: trends in prevalence of various drugs. . National Institute on Drug Abuse. National Institute on Drug Abuse Web. https://www.drugabuse.gov/drug-topics/trends-statistics/monitoring-future/monitoring-future-study-trends-in-prevalence-various-drugs. Accessed 22 March 2021.
Nurmedov S, Metin B, Ekmen S, Noyan O, Yilmaz O, Darcin A, Dilbaz N (2015) Thalamic and cerebellar gray matter volume reduction in synthetic cannabinoids users. Eur Addict Res 21:315–320. https://doi.org/10.1159/000430437
Paus T (2005) Mapping brain maturation and cognitive development during adolescence. Trends Cogn Sci 9:60–68. https://doi.org/10.1016/j.tics.2004.12.008
Peacock A, Bruno R, Gisev N, Degenhardt L, Hall W, Sedefov R, White J, Thomas KV, Farrell M, Griffiths P (2019) New psychoactive substances: challenges for drug surveillance, control, and public health responses. The Lancet 394:1668–1684. https://doi.org/10.1016/S0140-6736(19)32231-7
Peacock A, Bruno R, Gisev N, Degenhardt L, Hall W, Sedefov R, White J, Thomas KV, Farrell M, Griffiths P (2019) New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet 394:1668–1684. https://doi.org/10.1016/S0140-6736(19)32231-7
Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL (2013) Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269:100–108. https://doi.org/10.1016/j.taap.2013.03.012
Rodgman CJ, Verrico CD, Worthy RB, Lewis EE (2014) Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS Disord. https://doi.org/10.4088/PCC.13l01594
Schifano F, Orsolini L, Duccio Papanti G, Corkery JM (2015) Novel psychoactive substances of interest for psychiatry. World Psychiatry 14:15–26. https://doi.org/10.1002/wps.20174
Sidney S (2002) Cardiovascular consequences of marijuana use. J Clin Pharmacol 42:64S-70S. https://doi.org/10.1002/j.1552-4604.2002.tb06005.x
Solimini R, Busardo FP, Rotolo MC, Ricci S, Mastrobattista L, Mortali C, Graziano S, Pellegrini M, Di Luca NM, Palmi I (2017) Hepatotoxicity associated to synthetic cannabinoids use. Eur Rev Med Pharmacol Sci 21:1–6. http://www.europeanreview.org/wp/wp-content/uploads/1-6-Hepatotoxicityassociated-to-synthetic-cannabinoids-use. Accessed 22 Mar 2021
Su MK, Seely KA, Moran JH, Hoffman RS (2015) Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther 97:562–564. https://doi.org/10.1002/cpt.114
Sussman S, Skara S, Ames SL (2008) Substance abuse among adolescents. Subst Use Misuse 43:1802–1828. https://doi.org/10.1080/10826080802297302
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54:1–13. https://doi.org/10.3109/15563650.2015.1110590
Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo) 57:439–441. https://doi.org/10.1248/cpb.57.439
UNODC (2017) World Drug Report 2017. United Nations Publications. United Nations Office on Drugs and Crime Web. https://www.un-ilibrary.org/content/books/9789210606233. Accessed 22 March 2021.
UNODC (2018) World Drug Report 2018, United Nations Publications. United Nations Office on Drugs and Crime Web. https://www.un-ilibrary.org/content/books/9789210450584. Accessed 22 March 2021.
UNODC (2020) Current NPS Threats Volume II. United Nations Office on Drugs and Crime Web. https://www.unodc.org/LSS/Announcement/Details/16113474-647b-4425-8e52-4e5bc89a295a. Accessed 22 March 2021.
USDEA (2012) Schedules of controlled substances: placement of five synthetic cannabinoids into Schedule I, 21CFR Part 1308. In Administration, U. S. D. E. (Ed.), pp. 7. Federal Register Web. https://www.federalregister.gov/documents/2012/03/01/2012-4982/schedules-of-controlled-substances-placement-of-five-synthetic-cannabinoids-into-schedule-i. Accessed 22 March 2021.
Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL (2004) In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 56:909–915. https://doi.org/10.1016/j.biopsych.2004.10.015
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, Morris Q (2010) The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38:W214–W220. https://doi.org/10.1093/nar/gkq537
Weinstein A, Livny A, Weizman A (2016) Brain imaging studies on the cognitive, pharmacological and neurobiological effects of cannabis in humans: evidence from studies of adult users. Curr Pharm Des 22:6366–6379. https://doi.org/10.2174/1381612822666160822151323
White CM (2017) The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol 57:297–304. https://doi.org/10.1002/jcph.827
Wilson B, Tavakoli H, Dececchis D, Mahadev V (2013) Synthetic cannabinoids, synthetic cathinones, and other emerging drugs of abuse. Psychiatr Ann 43:558–564. https://doi.org/10.3928/00485713-20131206-08
Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, Rothschild MA, Bender K (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141–2153. https://doi.org/10.1007/s00216-010-4171-0
Yeruva RR, Mekala HM, Sidhu M, Lippmann S (2019) Synthetic cannabinoids-“spice” can induce a psychosis: a brief review. Innov Clin Neurosci 16:31–32
Yoon KS, Gu SM, Lamichhane S, Han KM, Shin J, Kim YH, Suh SK, Cha HJ, Yun J (2019a) Methoxetamine induces cytotoxicity in H9c2 cells: possible role of p21 protein (Cdc42/Rac)-activated kinase 1. Cardiovasc Toxicol 19:229–236. https://doi.org/10.1007/s12012-018-9489-4
Yoon KS, Yun J, Kim YH, Shin J, Kim SJ, Seo JW, Hyun SA, Suh SK, Cha HJ (2019b) 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo. Toxicol Lett 304:50–57. https://doi.org/10.1016/j.toxlet.2019.01.004
Yoon KS, Gu SM, Cha HJ, Kim YH, Yun J, Lee JM (2020a) 25I-NBOMe, a phenethylamine derivative, induces adverse cardiovascular effects in rodents: possible involvement of p21 (CDC42/RAC)-activated kinase 1. Drug Chem Toxicol. https://doi.org/10.1080/01480545.2020.1784924
Yoon KS, Lee JM, Kim YH, Suh SK, Cha HJ (2020b) Cardiotoxic effects of [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] acetate and 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol. Toxicol Lett 319:40–48. https://doi.org/10.1016/j.toxlet.2019.10.022
Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman DI (2008) Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 65:694–701. https://doi.org/10.1001/archpsyc.65.6.694
Yun J, Kim SY, Yoon KS, Shin H, Jeong HS, Chung H, Kim YH, Shin J, Cha HJ, Han KM, Hyeon S, Lee TH, Park HK, Kim HS (2016) P21 (Cdc42/Rac)-activated kinase 1 (pak1) is associated with cardiotoxicity induced by antihistamines. Arch Pharm Res 39:1644–1652. https://doi.org/10.1007/s12272-016-0840-7
Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo H, Shin J, Park HK, Kim HS, Kim YH (2016) Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res (Camb) 5:1663–1671. https://doi.org/10.1039/c6tx00259e
Yun J, Gu SM, Lee TH, Song YJ, Seong S, Kim YH, Cha HJ, Han KM, Shin J, Oh H, Jung K, Ahn C, Park HK, Kim HS (2017) Synthetic cannabinoid-induced immunosuppression augments cerebellar dysfunction in tetanus-toxin treated mice. Biomol Ther (Seoul) 25:266–271. https://doi.org/10.4062/biomolther.2016.116
Zawilska JB, Wojcieszak J (2014) Spice/K2 drugs–more than innocent substitutes for marijuana. Int J Neuropsychopharmacol 17:509–525. https://doi.org/10.1017/S1461145713001247
Zendulka O, Dovrtelova G, Noskova K, Turjap M, Sulcova A, Hanus L, Jurica J (2016) Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 17:206–226. https://doi.org/10.2174/1389200217666151210142051
Zorlu N, Angelique Di Biase M, Kalayci CC, Zalesky A, Bagci B, Oguz N, Gelal F, Besiroglu L, Gulseren S, Saricicek A, Bora E, Pantelis C (2016) Abnormal white matter integrity in synthetic cannabinoid users. Eur Neuropsychopharmacol 26:1818–1825. https://doi.org/10.1016/j.euroneuro.2016.08.015
Acknowledgment
This research was supported by a Grant (19182MFDS410, 20182MFDS422, and 20182MFDS425) from the Ministry of Food and Drug Safety in 2020 and the National Research Foundation of Korea (NRF) Grant funded by the Korea government (MSIT) (No. MRC, 2017R1A5A2015541, No. 2017R1C1B5017929).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chung, E.Y., Cha, H.J., Min, H.K. et al. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch. Pharm. Res. 44, 402–413 (2021). https://doi.org/10.1007/s12272-021-01326-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-021-01326-6